Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond
文献类型：期刊论文
| 作者 | Wei, Manman2; Wang, Xiang1; Song, Zilan2; Jiao, Mingkun2; Ding, Jian1 ; Meng, Ling-Hua1; Zhang, Ao2
|
| 刊名 | MEDICINAL RESEARCH REVIEWS
 |
| 出版日期 | 2015-07 |
| 卷号 | 35期号:4页码:720-752 |
| 关键词 | chronic lymphocytic leukemia PI3K inhibitor molecularly targeted therapy idelalisib |
| ISSN号 | 0198-6325 |
| DOI | 10.1002/med.21341 |
| 文献子类 | Review |
| 英文摘要 | Chronic lymphocytic leukemia (CLL) remains the most incurable leukemia. Early chemotherapeutic treatments, including alkylating agents, purine nucleoside derivatives, and immunotherapeutic antibodies, only show limited benefits for patients but severe off-target related side effects. Recent advances in understanding of the critical molecular pathways of regulating proliferation and survival of B-CLL cells have spurred a new therapeutical strategy by selectively targeting phosphoinositide 3-kinase delta (PI3K). Idelalisib, a first-in-class PI3K-selective small molecule has received the FDA's fast-track approval in July of 2014 as a new treatment of CLL, indolent B-cell non-Hodgkin's lymphoma, and relapsed small lymphocytic lymphoma. Undoubtedly, the success of idelalisib has provided a solid support in the development of PI3K-specific inhibitors and reformed the concept of treating CLL. However, the number of reported selective inhibitors of PI3K is very limited and very few have advanced into clinical trials. The mechanism of their actions remains elusive. More profound understanding on the modes of action of new PI3K inhibitors will further validate the PI3K-targeting strategy, and help to identify biomarkers capable of stratifying patients who will most likely benefit from the therapy. (C) 2014 Wiley Periodicals, Inc. |
| WOS关键词 | B-CELL RECEPTOR ; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR ; VIVO ANTITUMOR-ACTIVITY ; PHOSPHOINOSITIDE 3-KINASE ; SELECTIVE INHIBITOR ; KINASE INHIBITOR ; PI3-KINASE DELTA ; SURVIVAL SIGNALS ; CLINICAL-TRIALS ; IN-VITRO |
| 资助项目 | Chinese NSF[81125021] ; Chinese NSF[81373277] ; Chinese NSF[81430080] ; Chinese NSF[81321092] ; Major State Basic Research Development Program[2015CB910603] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000356068800004 |
| 出版者 | WILEY-BLACKWELL |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/276486]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 药物化学研究室 |
| 通讯作者 | Zhang, Ao |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Synthet Organ & Med Chem Lab, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Wei, Manman,Wang, Xiang,Song, Zilan,et al. Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond[J]. MEDICINAL RESEARCH REVIEWS,2015,35(4):720-752. |
| APA | Wei, Manman.,Wang, Xiang.,Song, Zilan.,Jiao, Mingkun.,Ding, Jian.,...&Zhang, Ao.(2015).Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond.MEDICINAL RESEARCH REVIEWS,35(4),720-752. |
| MLA | Wei, Manman,et al."Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond".MEDICINAL RESEARCH REVIEWS 35.4(2015):720-752. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。